NASDAQ:AMRS - Amyris Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.93 -0.09 (-1.79 %) (As of 04/23/2019 06:00 AM ET)Previous Close$5.02Today's Range$4.69 - $5.2952-Week Range$1.87 - $9.28Volume3.58 million shsAverage Volume3.73 million shsMarket Capitalization$377.27 millionP/E RatioN/ADividend YieldN/ABeta0.29 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Amyris, Inc., an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products. The company delivers its No Compromise products and services in markets, such as specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California. Receive AMRS News and Ratings via Email Sign-up to receive the latest news and ratings for AMRS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Industrial organic chemicals Sub-IndustryOil & Gas Refining & Marketing SectorBasic Materials Current SymbolNASDAQ:AMRS Previous Symbol CUSIP03236M10 CIK1365916 Webwww.amyris.com Phone510-450-0761Debt Debt-to-Equity RatioN/A Current Ratio0.44 Quick Ratio0.40Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$80.42 million Price / Sales4.69 Cash FlowN/A Price / Cash FlowN/A Book Value($4.64) per share Price / Book-1.06Profitability EPS (Most Recent Fiscal Year)($2.53) Net Income$-211,350,000.00 Net Margins-255.65% Return on EquityN/A Return on Assets-180.12%Miscellaneous Employees414 Outstanding Shares76,526,000Market Cap$377.27 million Next Earnings Date5/13/2019 (Estimated) OptionableOptionable Amyris (NASDAQ:AMRS) Frequently Asked Questions What is Amyris' stock symbol? Amyris trades on the NASDAQ under the ticker symbol "AMRS." When did Amyris' stock split? How did Amyris' stock split work? Shares of Amyris reverse split before market open on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split. How were Amyris' earnings last quarter? Amyris Inc (NASDAQ:AMRS) posted its quarterly earnings data on Monday, March, 18th. The biotechnology company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.44 by $1.51. The biotechnology company earned $19.36 million during the quarter, compared to analysts' expectations of $98.52 million. The firm's revenue for the quarter was down 76.0% compared to the same quarter last year. During the same period last year, the business posted $0.61 earnings per share. View Amyris' Earnings History. When is Amyris' next earnings date? Amyris is scheduled to release their next quarterly earnings announcement on Monday, May 13th 2019. View Earnings Estimates for Amyris. What price target have analysts set for AMRS? 2 brokers have issued 12 month target prices for Amyris' stock. Their forecasts range from $8.00 to $11.00. On average, they expect Amyris' share price to reach $9.50 in the next twelve months. This suggests a possible upside of 92.7% from the stock's current price. View Analyst Price Targets for Amyris. What is the consensus analysts' recommendation for Amyris? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amyris. What are Wall Street analysts saying about Amyris stock? Here are some recent quotes from research analysts about Amyris stock: 1. According to Zacks Investment Research, "Amyris INC is an integrated renewable products company applying industrial synthetic biology to genetically modify microorganisms to serve as living factories. Amyris designs these microorganisms to produce defined molecules for use as renewable chemicals and transportation fuels. The Company is engaged in the development of farmesene- a molecule, which serves as the base chemical building block for a wide range of renewable products to replace existing products that are derived from petroleum, plant or animal sources and that may be of lower quality or higher price. Amyris INC is headquartered in Emeryville, CA. " (1/15/2019) 2. HC Wainwright analysts commented, "We believe the company is capitalizing on its relationship with Xinfu / Yifan to monetize a portion of the long-term royalty opportunity upfront, which should lower quarterly volatility from this high-margin revenue stream while continuing to benefit from future royalty payments." (12/31/2018) Has Amyris been receiving favorable news coverage? News articles about AMRS stock have been trending negative on Tuesday, InfoTrie reports. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Amyris earned a coverage optimism score of -2.3 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an impact on the company's share price in the near term. Are investors shorting Amyris? Amyris saw a increase in short interest in March. As of March 29th, there was short interest totalling 17,586,473 shares, an increase of 27.1% from the March 15th total of 13,840,304 shares. Based on an average daily volume of 5,555,206 shares, the short-interest ratio is presently 3.2 days. Approximately 45.8% of the shares of the stock are sold short. View Amyris' Current Options Chain. Who are some of Amyris' key competitors? Some companies that are related to Amyris include Codexis (CDXS), Renewable Energy Group (REGI), Westlake Chemical Partners (WLKP), Green Plains (GPRE), FutureFuel (FF), REX American Resources (REX), Green Plains Partners (GPP), Sino United Worldwide Consolidated (SUIC), Solarwindow Technologies (WNDW), Dyadic International (DYAI), CTD (CTDH), Pacific Ethanol (PEIX), Tantech (TANH), Wave Sync (WAYS) and Gevo (GEVO). What other stocks do shareholders of Amyris own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Gevo (GEVO), Keryx Biopharmaceuticals (KERX), Novavax (NVAX), AVEO Pharmaceuticals (AVEO), Synergy Pharmaceuticals (SGYP), Advanced Micro Devices (AMD), MannKind (MNKD), BioDelivery Sciences International (BDSI), Exelixis (EXEL) and Ribbon Communications (RBBN). Who are Amyris' key executives? Amyris' management team includes the folowing people: Mr. John G. Melo, Pres, CEO & Director (Age 53)Ms. Kathleen Valiasek, Chief Financial Officer (Age 55)Mr. Eduardo Alvarez, Chief Operating Officer (Age 55)Ms. Nicole Kelsey, Gen. Counsel & Sec. (Age 52)Dr. Joel R. Cherry, Pres of R&D (Age 58) How do I buy shares of Amyris? Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Amyris' stock price today? One share of AMRS stock can currently be purchased for approximately $4.93. How big of a company is Amyris? Amyris has a market capitalization of $377.27 million and generates $80.42 million in revenue each year. The biotechnology company earns $-211,350,000.00 in net income (profit) each year or ($2.53) on an earnings per share basis. Amyris employs 414 workers across the globe. What is Amyris' official website? The official website for Amyris is http://www.amyris.com. How can I contact Amyris? Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected] MarketBeat Community Rating for Amyris (NASDAQ AMRS)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 253 (Vote Outperform)Underperform Votes: 337 (Vote Underperform)Total Votes: 590MarketBeat's community ratings are surveys of what our community members think about Amyris and other stocks. Vote "Outperform" if you believe AMRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/23/2019 by MarketBeat.com StaffFeatured Article: What is a stock split?